Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Increased risk of anemia, neutropenia and thrombocytopenia in people with HIV and well-controlled viral replication

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Blodsygdomme

    Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiFormidling

  3. Transcranial Alternating Current Stimulation Has Frequency-Dependent Effects on Motor Learning in Healthy Humans

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

In this study, we analyzed the evolution of the prognosis of primary central nervous system lymphoma (PCNSL) patients as they reach selected progression-free survival (PFS) milestones after high-dose methotrexate (HD-MTX)-based therapy. In total, 258 and 146 patients were included from Denmark and British Columbia, respectively. All patients were diagnosed during 2000-2017. The 5-year PFS was 27% (95% CI 23; 32); however, for patients reaching 5 years of PFS, this increased to 71% (95% CI 57; 86). Within the first 5 years after diagnosis, patients lost 2.0 years (95% CI 1.8; 2.2) when compared to a similar background population. This reduced to 0.5 years (95% CI 0.2; 0.9) for patients reaching 5 years of PFS. Treatment with rituximab was associated with improved outcomes. The prognosis of patients with PCNSL treated with HD-MTX-based regimens in this cohort is poor, although it improves as patients survive without progression/relapse. However, survival does not conclusively normalize to that of a similar background population.

OriginalsprogEngelsk
TidsskriftLeukemia and Lymphoma
Vol/bind60
Udgave nummer10
Sider (fra-til)2516-2523
Antal sider8
ISSN1042-8194
DOI
StatusUdgivet - okt. 2019

ID: 59260620